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1. ABSTRACT
This paper reviews the composition of colostrum 
and the potential preventive and therapeutic use of this 
“first milk” for treating various gastrointestinal disorders 
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in humans. Colostrum is a complex biological liquid that 
is richer in antimicrobial peptides, immune-regulating 
compounds and growth factors than the subsequent 
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mature milk. The main functions of colostrum are to 
provide essential nutritional components, strengthen the 
natural defense system, modulate immune response, 
balance intestinal microbiota and enhance the growth 
and repair of several tissues. Several studies and clinical 
trials carried out both in vitro and in vivo on humans and 
animals suggest the clinical benefits of bovine colostrum 
(BC) supplementation in gastro-intestinal diseases. 
Despite the encouraging results, further well-designed 
studies are required in order to confirm these effects, the 
dose and duration of treatment. Colostrum is safe since 
there are no contraindications regarding high dose levels 
and few side effects of clinical relevance have been 
reported. In conclusion, in the near future, colostrum-
based supplements may play a complementary role to 
synthetic drugs in the prevention and treatment of various 
gastrointestinal disorders.
2. INTRODUCTION
Colostrum is a biological fluid produced by 
the mammary gland after parturition, before it gradually 
loses its initial characteristics and to becomes mature 
milk. This secretion is fundamental for the survival 
of mammal offspring, especially for ungulates (1). 
Colostrum provides nutrition of newborns, enhances 
protection against pathogens, promotes the development 
of immune system and ensures the growth, maturation 
and repair of several tissues (2,3). Several studies have 
extensively analysed the composition of bovine, goat and 
human colostrum highlighting the presence of at least 
ninety different biologically active substances essential 
for specific functions (4). The bioactive components of 
colostrum include: i) anti-microbial factors, ii) immune-
stimulating peptides and iii) growth factors (5). Anti-
microbial factors provide passive immunity and protect 
against infections, especially during the first weeks of 
life. The anti-microbial activity of colostrum can be direct 
on pathogen agents or indirect by stimulating the growth 
of a healthy intestinal microbiota rich in Bifidobacteria 
and Lactobacilli (6,7). Colostrum provides signals to the 
immune system by inducing tolerance to food and non-
invasive antigens, thus avoiding the onset of an abnormal 
immune response while promoting its maturation and an 
adequate immune response against pathogens at the 
same time (8). Some components are able to promote 
the maturation and modulation of the immune system 
either directly as colostrinin, cytokines and lactoferrin, 
β-lactoglobuline, α-lactalbumin and glycomacropeptide 
or indirectly as oligosaccharides, gangliosides and 
nucleosides that favour the development of beneficial 
bacteria species (2,3,9). Furthermore, colostrum 
contains growth factors that play important roles in 
the development, maturation and repair of various 
tissues (10). In recent decades, BC have been used for 
the prevention and treatment of a variety of human and 
animal diseases, especially but not only of the gastro-
intestinal system (11,12). The aim of this review is to 
discuss the specific properties of some of the bioactive 
components of colostrum and to assess the potential 
clinical uses of colostrum in the prevention and treatment 
of various gastrointestinal disorders. This review is 
divided into three sections: 1) quality of colostrum; 2) 
constituents of colostrum and their functions; 3) clinical 
uses.
3. QUALITY OF COLOSTRUM
It is important to note that BC composition can 
vary and therefore product quality must be carefully 
evaluated when it is used as a supplement for humans 
and animals. The quality of BC depends on various 
factors: species, breed, farm management, collection 
period, number of parturitions and kids, animal health 
and processing practices. All these factors can influence 
the quality of BC by affecting the amounts of nutritional 
and biological active constituents, yet the most important 
factors affecting quality are probably collection period and 
processing procedures (13,14). In terms of composition, 
the best quality BC is produced during the first 24-48 hours 
after parturition. In fact, the levels of several bioactive 
components decrease in time-dependent manner (15). 
BC products should be manufactured in technologically 
advanced facilities using low-heat pasteurization and 
low-pressure processing procedures in order to avoid 
the denaturation of components especially those from 
protein nature (16). Finally, BC for human and animal 
use should be accompanied by a certificate attesting its 
quality, efficacy and safety e.g. absence of drug residues, 
environmental contaminants and contagious infectious 
agents. At present there is no standard composition that 
clearly defines the BC to be used as a dietary supplement 
in human and animals.
4. CONSTITUENTS AND THEIR FUNCTIONS
4.1. Anti-microbial and immune-stimulating 
factors
Are represented by compounds of various 
natures that, which provide passive immunity, protect 
the host against the pathogenic agents and can also 
modulate the immune system both directly and indirectly 
thus favouring the growth of beneficial bacteria. 
Immunoglobulins, lactoferrin, lactoperoxidase, lysozyme, 
α-lactalbumin and peptides derived from caseins such as 
glycomacropeptide (GMP) and whey proteins show high 
antimicrobial activity. Oligosaccharides, gangliosides and 
nucleosides provide protection against pathogens by 
acting as “false receptors” of intestinal cells. Moreover, 
they induce the proliferation of bifidobacteria and 
lactobacilli that not only inhibit the proliferation of the 
pathogens modulating the intestinal environment but also 
stimulate the immune system. Other components such 
as lactoferrin, colostrinin (CLN), cytokines and leucocytes 
have immune-modulatory functions.
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4.1.1. Immunoglobulins (Igs)
Concentrations in colostrum are very high 
and provide passive immunity to newborns during 
the development of their own immune systems but 
can also be useful for providing adults with protection 
against infection (17,18). Colostrum contains five 
classes of Igs: IgA, IgG, IgD, IgE, IgM that prove to be 
effective in defending the body against bacteria, virus, 
parasites and fungi (19). There is a rapid decrease in 
the Igs concentration levels of the milkings in the days 
following parturition (1). By following specific vaccination 
protocols to cows during pregnancy, it is possible to 
increase the Igs levels of colostrum thus producing 
hyperimmune colostrum that can be used against specific 
pathogens (20).
4.1.2. Lactoferrin (Lf)
Is a multifunctional iron-binding glycoprotein 
present in several exocrine fluids including colostrum. Lf 
concentration differs among species and rapidly decreases 
with subsequent milkings (21). The biological activities of Lf 
include anti-infective, anti-oxidant, proliferative and immune-
modulatory actions (22). Lf is directly effective against 
several bacteria, virus, fungi and protozoa species but 
could also have the indirect effect of modulating intestinal 
microbiota (23,24). Moreover, Lf increases the proliferation 
and differentiation of intestinal epithelial cells (25). Lf 
influences the immune functions such as cytokine production, 
cytotoxicity, proliferation, maturation, migration and activation 
of macrophages, granulocytes, natural killer and T and B 
cells by binding its specific receptor (22). In some conditions, 
Lf proves to have pro-inflammatory properties that induce 
macrophage activation (22).
4.1.3. Lysozyme
Is an enzyme that has anti-microbial action on 
gram negative and positive bacteria thanks to its ability to 
split the peptidoglycan layer of the bacterial cell wall thus 
causing the lysis of infectious agents (26).
4.1.4. Anti-oxidants
Colostrum contains several compounds 
with both pro and anti-oxidant effect depending on 
physiological status (27). The compounds that are able 
to counteract the action of reactive oxygen species are 
superoxide dismutase, catalase, glutathione peroxidise, 
vitamin A, E and C, ceruloplasmin, caseins and minerals 
as selenium, copper and zinc (28). Colostrum can be 
also considered to be a source of reactive oxygen 
species, since it presents macromolecules susceptible 
to peroxide processes as well as containing reactive 
oxygen species-generating systems such as xanthine 
oxidase and lactoperoxidase whose activities help to 
eliminate infectious agents (27).
4.1.5. Nucleotides/nucleosides
Are important as metabolites but also because 
they maintain the integrity of intestinal mucosa and 
influence the type of commensal flora as well as the 
proliferative action of growth factors (29,30).
4.1.6. Gangliosides
In colostrum and milk are associated with the 
membrane of fat globules at various concentrations 
depending on species (31). They are involved in various 
fundamental cellular functions and in immune response 
but also act as receptors for various bacteria and toxins. 
Gangliosides, in particular disialoganglioside 3 (GD3) are 
involved in the proliferation, maturation and activation of 
lymphocites, dendritic cells, in cytokine production and 
intestinal IgA secretion thus suggesting an involvement 
in immune response (32). GD3 can also affect the 
development of several organs including the digestive 
and nervous systems. Monosialoganglioside 3 (GM3) is 
involved in the defensive mechanisms of the host since 
they act as “false” receptors for toxins and adhesins 
of pathogens bacteria (33). Gangliosides may also 
stimulate the proliferation of useful microbiota such as 
bifidobacteria and therefore participate indirectly in host 
defensive mechanisms (34).
4.1.7. Oligopolysaccharides and 
glycolconjugate sugars
Colostrum contains many sugars such as 
glycolipids, glycoproteins, cellulose, glycosaminoglycan 
and mucin, in addition to lactose which is the main 
sugar (35,36). The soluble sugars of colostrum prevent 
the binding of bacteria and viruses to the intestinal cells 
by acting as “false” receptors (37). Some sugars such 
as fructo-oligosaccharides and galacto-oligosaccharides 
act as prebiotics in order to promote the growth and 
maintenance of healthy intestinal microbiota rich in 
Bifidobacteria and Lactobacilli (38). This beneficial 
bacteria produces several substances during its 
metabolism that inhibit the growth of harmful bacteria 
but also butyric acid which is used by intestinal epithelial 
cells (39). Furthermore, some Bifidobacteria and 
Lactobacilli strains can inhibit inflammatory responses in 
intestinal epithelial and immune cells (38).
4.1.8. Proline rich polypeptide or colostrinin 
(CLN)
The colostrum of several mammalian species is 
rich in CLN yet the largest amounts are found in bovine and 
human colostrum (40). CLN consists in several peptides 
that contain an unusually high portion of the amino acid 
proline and derive from the proteolysis of milk β-casein. Its 
biological activity is based on the action of more than one 
component and therefore poor activity levels are observed 
in the case of single components (41). CLN regulates 
the secretion of cytokines affecting both inflammatory 
and immune response. CLN is an intercellular signalling 
molecule that is able to modulate the immune system by 
regulating the proliferation and differentiation of immune 
cells both in vitro and in vivo (40). It stimulates weak or 
unreactive immune systems but can also restore the 
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balance of immune functions when the immune system 
is hyperactive as in the case of autoimmune diseases or 
allergies (42,43). CLN also plays an anti-oxidant role by 
reducing the levels of intracellular reactive oxygen species 
(ROS) and nitric oxide (NO) suggesting that it is able to 
control inflammatory response and those in which ROS 
are implicated in the pathogenesis (44). CLN has proved 
to have powerful immunomodulatory and neuroprotective 
properties that suppress chronic microglial cell activation 
and prevent the formation and increase the disruption 
of β-amyloid peptides (45). CLN induces the growth 
of neurons by modulating the expression of the genes 
responsible for the proliferation, differentiation and 
regeneration of cells in the nervous system and improves 
cognitive function in mammals (46,47).
4.1.9. Cytokines
Are proteins, peptides or glycoproteins secreted 
by specific cells of the immune system which are essential 
for cellular communication (48). Cytokines are produced 
in the mammary gland and then released in colostrum. 
Colostrum contains numerous cytokines, in particular with 
anti-inflammatory activity that can regulate the development 
of the neonate immune system, and control inflammatory 
response and the production of antibodies (49,50). They 
act in combination with other defensive components of 
colostrum such as Igs, lactoferrin and lactoperoxidase (51).
4.1.10. Leukocytes
Colostrum contains macrophages, lymphocytes 
and neutrophils that destroy the pathogens and parasites 
via phagocytosis (52). Furthermore, these immune 
cells modulating cytokine production can influence the 
development and the activity of the immune system of 
neonates (53).
4.2. Growth factors
Colostrum contains several growth factors that 
modulate the growth, maturation, function and repair 
of bone, muscle, nervous, connective, cartilage, skin 
tissues and particularly the gastro-intestinal mucosa (10).
4.2.1. Insulin-like growth factors I and II (IGF-I 
and IGF-II)
Also known as somatomedins are synthesized in 
the liver under the influence of the GH hormone and their 
receptors are found in the cells of various tissues, including 
the tissues of the gastro-intestinal tract (54). Somatomedins 
are carried in the blood by 6 types of proteins and promote 
the proliferation and differentiation of tissues as well as 
anabolic action by interacting with specific receptors (55). 
IGF-I is associated with cell proliferation in the crypts while 
IGF-II controls the mechanism of cell differentiation of 
intestinal epithelial cells (56).
4.2.2. Epidermal growth factor (EGF)
Is a peptide present in colostrum and its 
functions differ in neonates and adults. The EGF receptor 
is located in the basolateral membrane of the enterocyte 
and this suggests that it acts as readily available peptide 
surveillance for repairing injury sites in adults (57). In 
neonates, the growth factor can cross the intestinal barrier 
and binds to the receptor stimulating cellular growth (58). 
EGF may also prevent bacterial translocation in the gut 
and stimulates gut immunity (59).
4.2.3. Transforming growth factor-α (TGF-α)
Is a peptide present in colostrum and milk but it 
is also synthesized in the mucosa of the gastro-intestinal 
tract (60). Systemic administration of TGF-α stimulates 
the secretion of mucin, cell growth, wound healing and 
inhibits acid secretion. Its physiological role is cellular 
differentiation and migration rather than proliferation and 
it is useful for repairing and maintaining the integrity of 
intestinal epithelium (61).
4.2.4. Transforming growth factor-β (TGF-β)
Includes 5 isoforms of TGF-β and their 
binding site is the surface of the intestine (61). TGF-β 
inhibits cell proliferation, is a powerful chemo-attraction 
for neutrophils and plays a role in the repair process 
by stimulating the migration of epithelial cells on the 
denuded area to re-establish epithelial continuity (62). It 
regulates the inflammatory and immune response in the 
intestinal mucosa by intervening in T helper lymphocytes 
differentiation and IgA production (62,63).
4.2.5. Platelet-derived growth factor (PDGF)
Is a peptide obtained from platelets but is also 
produced by macrophages. PDGF is a potent mitogen for 
fibroblasts and facilitates the healing of ulcers (64).
4.2.6. Vascular endothelial growth factor (VEGF)
Is a peptide with potent angiogenic and mitogenic 
activity, which acts on vascular permeability (65). VEGF 
is present in colostrum and its receptor is located on the 
apical membranes of epithelial cells (66). These findings 
suggest a role for VEGF in digestive system physiology.
5. CLINICAL APPLICATIONS
This section of the review reports the effects of 
colostrum on various disorders of the gastro-intestinal 
tract, in particular those accompanied by inflammatory 
processes, by referring to relevant in vitro and in vivo 
studies (67-69). It is also important to note that some of 
these studies were of poor methodological quality therefore 
the results could not be confirmed by other researchers. 
BC may provide insights into the prevention and treatment 
of gastro-intestinal disorders, but further studies are 
required before it can be used for human beings.
5.1. Acute infectious diarrhoea
Is a common problem in developing countries 
and for travellers who visit them. It is usually caused 
by bacterial, viral, or parasitic infection. It could be 
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associated with inflammation, intestinal damage, 
increased intestinal permeability, bacterial translocation 
and multiple organ dysfunctions. Supportive therapy 
(appropriate diet, fluid therapy) should be considered for 
all patients suffering from diarrhoea, while antimicrobials 
are not recommended as enteropathogens are often 
associated with self-limiting diarrhoea. Numerous in vivo 
and in vitro studies have shown that BC is beneficial in the 
prevention and treatment of infective gastroenteritis for 
various animal species, including human beings (70-74). 
Colostrum and hyperimmune colostrum are effective 
against a wide variety of intestinal pathogens. Rotavirus 
is a common cause of viral gastroenteritis in infants 
and children for which there is not currently an effective 
vaccine, therefore a new strategy is required in order to 
reduce the duration and severity of clinical signs. The 
treatment of rotavirus-infected infants with hyperimmune 
BC reduced the duration of diarrhoea and excretion of 
virus, and the passive immunization of healthy infants with 
colostrum antibodies reduced the incidence and duration 
of diarrhoea compared to the placebo group (75-77). On 
the contrary, the treatment of hospitalized infants with 
hyperimmune BC did not reduce the duration and severity 
of diarrhoea (78). In a mouse animal model, multiple 
administration of BC before the inoculation of rotavirus 
resulted in earlier recovery from diarrheal symptoms (74). 
Enterotoxigenic Escherichia coli commonly causes 
diarrhoea in travelers and infants in developing countries. 
Several studies have proved the effectiveness of BC in 
preventing infection caused by E. coli (79-83). Otto et al., 
reported that a tablet formulation of hyperimmune BC 
was more effective than placebo in protecting human 
volunteers against the development of diarrhoea caused 
by the bacteria (80). In a randomized, double-blind, 
controlled field trial, hyperimmune BC-fed infants showed 
a reduction in incidence and duration of diarrhoea 
compared to formula-fed infants (84). Two clinical studies 
showed that the administration of anti-E. coli IgG obtained 
from BC before oral challenge with enterotoxigenic 
Escherichia coli was effective in preventing clinical 
diarrhoea (85,86). Clostridium difficile is a bacterium 
that has proved to be the main cause of infectious 
diarrhoea. In gnotobiotic piglets with Clostridium difficile 
infection the administration of hyperimmune BC reduced 
the development of diarrhoea and colitis, in respect to 
control animals (20). In another study, hamsters treated 
prophylactically with hyperimmune BC were protected 
against C. difficile infection (87). In humans, anti-C. difficile 
hyperimmune BC was as effective as metronidazole 
in the prevention of bacterial infection (88). Finally, 
in vitro studies showed that hyperimmune BC inhibits the 
adhesion of C. difficile to enterocyte-like caco-2 cells and 
was effective in neutralizing A and B toxins in cultured 
tissue (87, 89). Protozoa such as Criptospridium parvum 
or Entamoeba histolytica and Candida albicans fungi can 
also cause acute diarrhoea (90-93). Cryptosporidium 
species generally cause chronic diarrhoea in 
immunocompromised individuals. Oral administration of 
hyperimmune BC in immunocompromised children and 
adults proved to be effective for treating cryptosporidiosis 
and in the prevention of cryptosporidiosis in healthy 
volunteers when administered before challenge with 
C. parvum spores (91,92). Immunoglobulins concentrate 
obtained from hyperimmune BC, was effective in treating 
diarrhoea in C. parvum-infected AIDS patients (93). 
The prophylactic and therapeutic effect of colostrum 
may be due to several compounds which can act in 
the various phases of the infective disease: they can 
eliminate the pathogens, improve the intestinal barrier 
functions, normalize host intestinal flora, inhibit bacterial 
translocation and modulate immune response by 
reducing the severity of inflammation (81, 94-100).
5.2. Helicobacter spp infections
Although Helicobacter species are commonly 
found in healthy humans and pets, this bacterium is 
found in 100% of the subjects presenting symptoms of 
chronic vomiting and malnutrition. H. pylori is the main 
species found in humans, H. Bizzozeronii is found in 
dogs while H. felis and H. heilmannii are the species 
most commonly found in cats (101). Helicobacter 
infections can cause inflammation of the tissues lining the 
stomach and duodenum thus causing acute and chronic 
gastritis, duodenitis, and peptic ulcers. The clinical signs 
of the infection are represented by nausea, vomiting, 
diarrhoea, abdominal pain, lack of appetite or anorexia 
and weight loss. Therapy consists in a combination of two 
antibiotics and an antisecretory drug, such as a proton-
pump inhibitor or a H2-receptor antagonist, which shows 
a low percentage of eradication of the bacteria and 
various side effects such as diarrhoea due to intestinal 
dysbiosis and the selection of Clostridium difficile (102). 
Several in vitro and in vivo studies performed in mice 
have proved the effectiveness of BC in preventing 
and treating the Helicobacter infection (103,104). The 
beneficial effect of colostrum may have inhibited the 
invasive capacity of pathogen bacteria, modulation 
of immune response and favoured mucosal repair as 
highlighted by various in vitro studies (10,68,105-108). 
Daily administration of hyperimmune colostrum to adults 
or children for 4 weeks reduced the severity of clinical 
signs and inflammation but only eradicated the bacteria 
in few patients (109,110). However, the administration 
of hyperimmune colostrum to adult H. pylori-infected 
patients had no significant effect on the urea breath test 
or histological H. pylori count (111). In another study 
performed in H. pylori-positive infants colostrum was not 
able to eradicate H. pylori as assessed by the urea breath 
test (112). Further well-designed studies are required in 
order to evaluate the effectiveness of BC in preventing 
and treating the Helicobacter infection.
5.3. Drug-induced diarrhoea
The most common drugs that cause diarrhoea 
are antibiotics, chemotherapy drugs and non-steroidal 
anti-inflammatory drugs (NSAIDs).
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5.3.1. Antibiotics
are commonly used for treating several 
infectious diseases and can benefit both animal and 
human health. Occasionally, oral antibiotics can cause 
unwanted adverse effects like diarrhoea due to changes in 
intestinal microbiota. Dysbiosis can favour the selection of 
opportunistic or pathogenic bacteria such as Clostridium 
difficile, which is a frequent complication of long-term, 
broad-spectrum antibiotic therapy (20). Furthermore, 
microbial imbalance can also cause changes in intestinal 
homeostasis with increased permeability, bacterial 
translocation, abnormal immune response, and strong 
inflammatory reaction can occur (97-100). Colostrum 
and hyperimmune BC administration at the start of 
antibiotic treatment may reduce the risk of antibiotic-
associated diarrhoea; selection of Clostridium difficile 
and it may also have a positive effect in regulating the 
immune system (2, 6,12,20,51,70,113). Moreover unlike 
conventional antimicrobials, BC favours the growth of 
beneficial bacterial populations by avoiding antibiotic-
resistant organisms (20,95).
5.3.2. Chemotherapy
Cancer is one of the most common diseases 
of this century effecting both humans and animals. Most 
tumours are treated with chemotherapy. Chemotherapic 
agents have strong side effects on rapidly growing and 
self-renewing tissues such as intestinal and oral mucosa, 
bone marrow and hair follicles. Chemotherapeutic agents 
cause “intestinal mucositis”, a condition characterized 
by apoptosis and loss of cellular proliferation in the 
intestinal epithelium, resulting in crypt loss, villus atrophy 
and ulcerations that increase gut permeability, bacteria 
translocation and bleeding (114). Chemotherapy also 
induces immunosuppression increasing the risk of 
opportunistic infections and inflammations due to 
alterations in gut microbiota (115,116). One of the side 
effects of chemotherapy is “oral mucositis” causing pain 
and inflammation to the lining of the mouth (114). To date, 
there are no available drugs that can prevent mucositis. If 
severe lesions occur in the gastro-intestinal tract, it may 
be advisable to reduce the dose or discontinue treatment 
that consequently reduces the effectiveness of the 
chemotherapy. New strategies for protecting tissues and 
stimulating their recovery may increase the chemotherapy 
dose and the duration of the treatment (117,118). The 
administration of colostrum reduced gut toxicity during 
myeloablative chemotherapy in piglets (119). Growth 
factors included in BC in high concentrations as TGF-β, 
EGF and IGF-I aided the recovery of rat intestinal mucosa 
damaged by methotrexate and improved chemotherapy-
induced mucositis (120,121). Satisfactory results were 
not obtained in all of the studies, EGF only had a minor 
beneficial effect in reducing oral ulcerations in patients 
undergoing chemotherapy (122). Colostrum contains 
antimicrobial and growth factors that, by fighting infection 
and stimulating cellular proliferation, may be used as 
adjuvant therapy for treating the intestinal mucosa in 
combination with or following chemotherapy in order to 
reduce the detrimental effects of chemotherapic drugs 
in tissues (10,12,68,94,123,124). Finally, BC can reduce 
body weight loss associated with the treatment (125,126).
5.3.3. Non steroidal anti-inflammatory drugs 
(NSAIDs)
Are among the drugs most commonly used 
worldwide due to their anti-inflammatory, analgesic and 
antipyretic effects both in human and in animals (127). 
However, NSAIDs are associated with a broad spectrum 
of side effects, mainly in the upper gastrointestinal 
tract. These drugs cause gastro-intestinal damage by 
reducing the mucosal gastric barrier and blood flow and 
stimulating apoptosis with predisposition to inflammation 
and mucosal ulcerations (109,128). NSAIDs can also 
alter the microbiota thus causing the overgrowth of 
Gram negative and anaerobic bacteria that results in 
the over secretion of pro-inflammatory cytokines and 
bacterial translocation (129,130). Current therapeutic 
options include coadministration of acid suppressants, 
prostaglandin analogues and relatively selective 
cyclooxygenase II inhibitors. However, none of these 
options are optimal and new approaches are required. It 
is likely that many of the mechanisms caused by NSAIDs 
to determine their side effects may be counteracted by the 
biologically active components present in BC which work 
in an additive or synergistic way (10,68). BC contains 
various growth factors that can stimulate the healing 
of ulcers as well as other compounds that can control 
inflammatory response, infections and epithelial barrier 
functions and are useful in the event of gastrointestinal 
injuries (68,131-133). Various models have been used 
to evaluate the effect of colostrum in reducing intestinal 
lesions and stimulating their repair (64,124,134-136). 
With regard to indomethacin-induced enteropathy, both 
prefeeding and postfeeding mice with BC facilitated the 
growth of intestinal villi, thus indicating preventive and 
healing effects (124). Colostrum-based supplements 
reduced gut damage and bacterial translocation in 
rats caused by diclofenac (134). In a rat model of 
gastric injury and a mouse model of intestinal injury, 
BC reduced the severity of the lesions caused by the 
administration of indomethacin (136). Furthermore, an 
in vitro study showed that BC increased proliferation and 
cell migration of RIE-1 and HT-29 cells (136). Colostrum 
reduces gastric and intestinal lesions, permeability 
of the intestinal wall, bacterial translocation and 
shortening of villi (124,137,138). In human volunteers, 
the co-administration of BC and indomethacin reduced 
gut permeability in respect to the control group that 
only received the anti-inflammatory drug (137). Kim 
et al., showed that the combined administration of BC 
and diclofenac in rats reduced the increase in intestinal 
permeability, changes of microbiota and villous damage 
caused by diclofenac (138). BC may prove to be useful 
for the prevention and treatment of intestinal ulcerative 
conditions.
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5.4. Immunodeficiency diarrhoea
Immunodeficiency is a state in which the ability 
of immune system to fight infections is compromised 
or entirely absent and immunocompromised subjects 
may be particularly vulnerable to opportunistic 
infections. Most infectious causes of immunodeficiency 
are due to viral infections (HIV in humans) that attack 
the immune system and reduce the number and the 
function of immune cells. The intestine is a common 
site of opportunistic infection and the main symptoms 
are diarrhoea associated with progressive weight loss. 
Diarrhoea in immunocompromised patients can be 
caused by common pathogens, including viruses, fungi, 
bacteria and protozoa, in particular Criptosporidium 
parvum and Giardia species (139). Current treatments 
include antibiotics, blood transfusions, corticosteroids, 
dietary supplements, immunomodulatory and antiviral 
drugs which may only help to alleviate symptoms and may 
cause strong side effects (140). In this regard, alternative 
and/or adjuvant strategies should be evaluated. Several 
studies have suggested that BC might improve the 
clinical conditions of HIV-associated diarrhoea, probably 
thanks to the synergic action of several biologically 
active molecules contained in BC (93,141,142). Good 
results have been obtained by administering colostrum 
to human patients which has improved clinical conditions 
by reducing abdominal pain, diarrhoea score and 
fatigue (91,143). In another study BC reduced daily 
stool frequency and increased the body weight and body 
mass index and CD4+ count respect to the control (144). 
Furthermore, a lipid defined as sporozoites inhibiting the 
adhesion of lipid (SIL) has been identified in colostrum 
and the intestinal mucosa of calves fed with colostrum, 
which also acts against Giardia (145). Colostrum has 
been used effectively for reducing the clinical signs and 
elimination of oocysts in various animal species (146). 
This suggests that BC can ameliorate HIV-associated 
diarrhoea, probably through direct antimicrobial and 
endotoxin-neutralizing effects, thus suppressing bacterial 
translocation and gut inflammation as well as favouring 
mucosal integrity and tissue repair (6,12,51,138). Further 
research must be carried out to confirm these findings.
5.5. Inflammatory bowel disease (IBD)
Are a heterogeneous group of chronic, 
multifactorial, relapsing inflammatory diseases of 
the gastro-intestinal tract (147). Common clinical 
signs observed in IBD patients are chronic diarrhoea, 
vomiting and weight loss associated to histopathological 
evidence of inflammation in various portions of GI tract. 
In humans, Crohn’s disease (CD) and ulcerative colitis 
(UC) are the principal types of IBD. In pets, especially 
in dogs, several kinds of chronic diseases have been 
reported which present both differences and similarities 
with human IBD (148). While the exact aetiology of 
IBD remains unknown, several clinical studies suggest 
that interplay between genetic, environmental, immune 
factors and enteric bacteria play a critical role in the 
development of the disease (149). It has been suggested 
that atypical intestinal microbiota induces an incorrect 
activation of the gut immune system resulting in loss 
of tolerance and consequently a chronic inflammation 
of the digestive tract in genetically predisposed 
subjects (150). Intestinal microbiota confer important 
functions to the host including mucosal barrier, metabolic 
and immune regulatory functions (151). Evidence from 
recent molecular studies revealed differences in the 
intestinal microbiome between healthy individuals 
and IBD patients with a reduction of beneficial and an 
increase of potentially dangerous bacteria (152). Current 
therapy for treating IBD includes the administration of 
aminosalicylate, steroids, immunosuppressive agents 
and antibiotics; although it is not curative and has several 
side effects (153). New approaches are required for 
the prevention and/or treatment of IBD, and BC can 
represent a safe, low cost option (154). Prophylactic 
administration of BC reduced weight loss, decreased 
colon shortening and improved the histologic severity 
of colon inflammation in dextran sulfate sodium-induced 
colitis in mice. Furthermore, these beneficial effects were 
accompanied by the reorganisation of immunoregulatory 
cells (155). In the same animal model of colitis, BC 
therapy improved occult blood, stool consistency, and 
clinical recovery from colon inflammation but did not 
reduce body weight loss (156). BC enema resulted in 
the improvement of clinical signs and histological scores 
in human patients affected by active colitis compared 
to control (157). It is possible that BC components can 
balance intestinal microbiota thus favouring the growth 
of beneficial bacteria that in turn reinforce the mucosal 
barrier function, neutralize pathogen agents and reduce 
the risk of bacterial translocation (18,100,132,158). 
Other substances included in BC can help to modulate 
immune system cells and consequently the severity 
of inflammatory response while colostrum can induce 
epithelial regeneration (2,51,70,94,99,100,124).
5.6. Necrotizing enterocolitis (NEC)
Is a serious disease characterized by severe 
ulceration of the small and large intestine that affects 
infants and mainly pre-term neonates. The precise 
aetiology of NEC remains unknown, although several 
structural and functional deficiencies related to epithelial 
barrier integrity, digestive and absorptive capacity, 
intestinal mobility, gut microbiota and immunological 
dysfunctions are definitely involved in the development 
and progression of the disease (159,160). Maldigestion 
and intestinal stasis commonly observed in preterm 
infants can lead to abnormal gut microflora, bacterial 
translocation and sepsis, which contribute to an aberrant 
activation of the immune system and finally to uncontrolled 
inflammation (161). A feasible strategy for reducing the 
incidence of NEC could be to control the type of diet and 
feeding mode since the maturation of the gastrointestinal 
tract, bacterial colonization and the modulation of the 
immune system depend on these factors (123,162-164). 
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The synergic action of biologically active components of 
BC may contribute to the maturation of the digestive tract, 
in balancing gut microbiota, modulation of the intestinal 
immune system and mucosal repair (2,10,12,57,124). 
Colostrum has proved to have beneficial effects and 
therefore may represent an adjuvant therapy (165-167). 
It was suggested that BC is effective in stimulating gut 
structure, function, and NEC resistance in preterm 
piglets (168). Animals fed with BC had a longer intestinal 
transit time, higher weight gain, absorptive capacity 
and enzyme activities compared to piglets fed with 
infant formula. At the same time, BC reduced NEC 
incidence, pro-inflammatory cytokines concentration 
such as IL-8 and reduced histological lesions (169). BC 
proved to have beneficial effects on NEC development 
and intestinal function in a piglet model and these 
data were confirmed by an in vitro study in which a 
modulatory action of colostrum proteins in cytokines 
secretion from bacteria-stimulated murine bone marrow-
derived dendritic cells was observed (170). An in vitro 
study suggested that pretreatment with BC significantly 
reduced several bacteria specie (Enterobacter cloacae, 
Klebsiella oxytoca, Escherichia coli, Serratia marcescens 
and Klebsiella pneumonia) in attachment to HT-29 cells, 
although the treatment increased the levels of some pro-
inflammatory cytokines (171). Intestinal function was 
restored by BC administration after initial formula-induced 
inflammation in a pig model of NEC. NEC severity and 
pro-inflammatory cytokine (IL-1β and IL-8) concentrations 
were lower, while villus height, galactose absorption, 
and brush-border enzyme activities increased in the 
intestines of the piglets fed with colostrum compared to 
the control (172,173). In clinical studies, the piglets fed 
with infant formula showed higher percentages of NEC 
development, structural damage, reduced functional 
activity and antioxidant levels and bacterial overgrowth 
compared to animals fed with BC (167,174). Colostrum 
administration may decrease clinical sepsis, inhibit 
secretion of pro-inflammatory cytokines and increase 
levels of circulating immune-protective factors in 
extremely premature infants (175). Nevertheless, further 
studies are required to confirm these encouraging results 
and to determine whether BC could be used as an 
effective substitute of mother’s milk for preterm infants.
5.7. Short bowel syndrome (SBS)
Is characterized by insufficient length of 
the intestine due to surgical amputation and it is 
associated with poor digestion and absorption. The 
most common therapeutic option is parenteral nutrition 
but other strategies are required in order to improve 
the outcome of patients that depend on the functional 
adaptation of the remaining intestine. Colostrum contains 
immunoregulatory, antimicrobial and trophic components 
that can support intestinal development and function in 
neonates and could also enhance intestinal adaptation and 
functions (2,37,94,172). A possible strategy for improving 
conditions of patients is to decrease the intestinal transit 
of nutrients and allow a longer mucosal contact time 
for their absorption by increasing muscular adaptation. 
Colostrum supplement induces muscular hypertrophy 
increasing the muscle width and the number of cells and 
these changes may be mediated by the simultaneous 
increase of the serum concentrations of IGF-1 and 
IGF binding proteins after small intestinal resection in 
piglets (176). In a pig model of SBS colostrum induced 
intestinal adaptation, the piglets that underwent massive 
intestinal resection showed the same weight gain and 
greater villus length and crypt depth in the jejunum and 
ileum compared to the control (177). On the contrary, in 
a randomized controlled trial Lund et al., observed that in 
spite of it high content of bioactive factors, colostrum did 
not significantly increase intestinal functions, absorption 
and body composition compared with the control (178). 
Feeding the piglets with colostrum supplement increased 
intestinal proliferation significantly (179). Furthermore, 
the high levels of specific growth factors contained 
in colostrum may prove to be beneficial. Systemic 
administration of EGF stimulates intestinal growth in 
rats receiving parenteral nutrition (57,68). In rabbits that 
underwent intestinal resection, the oral administration 
of EGF proved to restore glucose transport (180). 
Therapeutic use of colostrum in SBS may be especially 
useful for treating children given that gut adaptation is 
better during the development of the gastro-intestinal 
tract rather than in adults. Additional research is required 
in order to determine whether this practice can improve 
the outcome of patients with SBS.
5.8. Surgery
Nosocomial infections present serious clinical 
issues in surgery despite the progress made in hygiene, 
surgical techniques and intensive care medicine. Under 
conditions of shock caused by injury or surgery, bacteria 
and endotoxins in the intestines can cross the mucosal 
barrier by translocation and enter the blood and lymphatic 
system sometimes causing a dangerous systemic 
inflammatory response syndrome (SIRS) and a multiple 
organ dysfunction syndrome (MODS) (181). In humans, 
bacterial translocation has a prevalence of approximately 
15% in elective surgical patients and occurs more 
frequently in patients undergoing abdominal surgery, 
organ donors and intestinal obstruction, but is also evident 
in patients with chronic inflammatory bowel diseases, 
ischaemia–reperfusion injury shock, pancreatitis and 
immunocompromised subjects (132,182). In general, 
current therapeutic options include coadministration of 
fluids and vasopressors to preserve blood pressure, blood 
in the event of bleeding, antibiotics to counteract infections 
and bacterial translocation, corticosteroids or NSAIDs to 
control inflammation, painkillers or other analgesic drugs 
and diet control. In this context, colostrum administered 
before or after surgery could play a complementary role 
to conventional therapy with the aim of reducing the risk 
of complications. Colostrum has been identified as being 
a preventive treatment in pre-operatory abdominal and 
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coronary arteries surgery. In abdominal surgery it reduced 
endotoxemia while in coronary bypass surgery it reduced 
IL-6 and C-reactive protein levels although it did not have 
any effect on endotoxemia (183,184). Several in vitro 
and in vivo studies have been carried out to evaluate 
the effectiveness of colostrum in preventing bacterial 
translocation, endotoxaemia and increasing morpho-
physiological adaptation after small bowel surgery in 
rats and rabbits (132,138,185,186). It is believed that 
preoperative treatment with colostrum, associated with 
conventional therapy, may reduce bacterial translocation 
and endotoxemia thus favouring the recovery of both 
human and animal surgical patients (99,132,187). It 
contains numerous components that can directly or 
indirectly affect the various pathogenetic steps of the 
complications linked to surgery (20,97). Furthermore, 
the synergic activities of components present in 
colostrum can be useful in the postoperative period to 
ensure wound healing and the recovery of absorptive 
functions (129,162,176,188).
5.9. Side effects and contraindications
According to the current state of knowledge, 
colostrum appears to be safe and no contraindications 
are observed even when administered at high 
concentrations both in humans and animals (189,190). 
Some authors have reported lactose intolerance, 
nausea, flatulence, transient diarrhoea and unspecified 
abdominal discomfort as possible side effects while 
other studies specifically reported the absence of side 
effects (83,128,129,165,137,143,189,190). However, 
further research is required in order to confirm these 
data, and, more importantly, to evaluate the effects of 
colostrum when used for a prolonged periods of time 
and during pregnancy. Milk allergy is the most frequent 
food allergy in infancy and childhood. Like milk colostrum 
contains caseins, a-lactalbumin and β-lactoglobulin, and 
other minor proteins (immunoglobulins, bovine serum 
albumin) that are deemed to be the main allergens (191). 
For this reason, colostrum is not recommended for 
treating individuals who are sensitive to milk proteins.
6. CONCLUSION
Colostrum is a rich source of nutrients and 
biologically active molecules that are essential for 
several specific functions including defensive action, 
the modulation of immune response, the balancing 
of intestinal microbiota and the growth and repair of 
several tissues. The components of colostrum, acting 
synergistically, can intervene in various pathogenetic 
phases of several diseases, thus contributing to an 
improvement of clinical symptoms. Colostrum may also 
have a preventive action or reduce the side effects 
of several drugs that are currently used for treating 
various diseases of humans and animals. It may also 
play an important role in accelerating the recovery of 
health and body weight during convalescence. More 
generally, colostrum may be administered with the aim 
of maintaining a good health status, strengthening the 
immune system and preventing disease. Current farming 
methods foresee the production of large quantities of raw 
colostrum for continuous availability. Colostrum used as 
supplement must be of high quality and a standardization 
of the product is required. Pharmaceutical companies 
aim to produce commercial products containing 
bovine colostrum while biotechnology companies 
attempting to clone and produce large quantities of its 
main components. The growing interest in this natural 
biological fluid is supported by the encouraging results 
obtained in scientific studies and clinical trials carried out 
both in vitro and in vivo in humans and animals, although 
further research is required to confirm its potential and 
long-term effects. Colostrum is safe and does not have 
contraindications even at high dose levels and there 
are few reported side effects of clinical relevance. 
Therefore in the near future, this “first milk” may play a 
complementary role to synthetic pharmaceutical drugs, 
in the prevention and treatment of several diseases of 
humans and animals and it may improve the daily health 
of populations in developing countries.
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